Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

ATLANTA, Dec. 10, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

The Phase 2 ACE study recruited patients into two separate cohorts of patients with relapsed/refractory AML, and the results from each cohort of were presented in individual oral sessions.  Highlights of the combined key findings in FLT3-ITD positive patients were as follows:

  • Approximately 50 percent of FLT3-ITD positive patients achieved a CRc, or composite complete response (CRc: complete remission (CR) + complete remission with incomplete platelet recovery (CRp) + complete remission with incomplete hematologic recovery (CRi)),
  • Approximately 50 percent of FLT3-ITD positive patients who were refractory (i.e. had no response to their prior AML therapy) achieved a CRc,
  • Approximately one-in-three FLT3-ITD positive patients who had relapsed or were refractory after two prior lines of treatment or after a prior hematopoietic stem cell transplant (HSCT) received a potentially curative HSCT following treatment with quizartinib,
  • As of Sept. 28, 2012, 35 (18 percent) FLT3-ITD positive patients had survival of greater than 12 months

"AML is amongst the most challenging hematological malignancies to treat, and patients with activating FLT3 mutations have a particularly poor prognosis and often relapse or are refractory to current treatment options," said Jorge Cortes, M.D., Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.  "
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
8. Xstelos Holdings Announces Dividend
9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... -- The legalization of medical and recreational marijuana is ... new economic driver – that has taken legislators by ... response to the will of the people about a ... a National Press Club Newsmakers news conference on Thursday, ... the area of marijuana legalization will discuss its far-reaching ...
(Date:7/14/2014)... 2014 Decision Resources Group finds that ... perceptions of emerging drugs for both oncologists and ... (50 medical oncologists and 50 hematological oncologists) and ... care organizations (MCOs), reveals that despite lower familiarity ... of payers say this designation will likely influence ...
(Date:7/14/2014)... HAMILTON, N.J. , July 14, 2014 /PRNewswire/ ... Group, LLC is pleased to announce that its ... the Association for the Assessment and Accreditation of ... humane treatment of animals in science worldwide through ... highest standards for animal care and use in ...
Breaking Medicine Technology:NPC Newsmaker Program: Interpreting smoke signals from the marijuana skirmish line 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2
... Accuray Incorporated, (Nasdaq:  ARAY), a global leader in the ... leading academic institutions using CyberKnife radiosurgery in breast cancer ... Southwestern and Fox Chase Cancer Center, will be presented ... for Radiation Oncology (ASTRO) in San Diego from October ...
... 30 Researchers from the University of Bari, Italy, ... creates a sustained viral response (SVR) and protects them ... to determine the long-term clinical outcomes of patients posttransplant ... (HCV) infection of the liver graft. ...
Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Along with improving vision, ... Alzheimer,s disease and other types of dementia, a new ... of life, the researchers said. "These preliminary results ... benefits for people with dementia and their loved ones, ... Case Western Reserve University and University Hospitals Case Medical ...
(Date:7/14/2014)... 2014 (HealthDay News) -- Being physically active in middle ... disease and other types of dementia, suggest the findings ... found that physical exercise at various levels, especially in ... from the Mayo Clinic, said in an Alzheimer,s Association ... are not yet conclusive. More research is needed to ...
(Date:7/14/2014)... By Amy Norton ... -- Older adults who enjoy mentally stimulating games may have ... research suggests. The study looked at the connection between ... mental acuity for adults in their 50s and 60s. ... every other day performed better on tests of memory and ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up ... run and one-mile family fun walk. The run begins ... and finishes inside Levi’s® Stadium. , Over the past ... the Mission City Community Fund. All proceeds benefit education, ... Seasoned athletes, part-time pavement-pounders and walkers are invited to ...
Breaking Medicine News(10 mins):Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... for patient ... care, ... Sutter Health hospitals currently in,bargaining have voted overwhelmingly to authorize a strike ... Nurses Organizing Committee announced today. There has,been no progress in bargaining over ...
... for humans, it offered immunity for at least 6 months ... anthrax vaccine proved highly effective in tests in mice and ... , After it was placed inside the animals, noses, the ... survived after they received injections of 1,000 times the lethal ...
... AMCS ),a leader in radiology and medical image and information ... the,Thomas Weisel Partners Healthcare Conference 2007 being held in Boston. ... -- Thursday, September 6, 2007 ... a.m. (Eastern Time), ...
... Cleveland-based The ScottCare,Corporation, a leader in ... telemetry, announced today that,the company has completed ... Rozinn Electronics, Inc., a privately-held market leader ... "We are very pleased to welcome ...
... BlueShield of South,Carolina has created a new division ... Davis to vice president in charge of the ... CEO M. Edward Sellers and is,responsible for enhancing ... a corporate-wide executive development program. "We are ...
... the September issue of The American Naturalist, Juan Carranza ... Javier Prez-Barber a (Macaulay Institute, United Kingdom) offer a ... to intense competition are born with lower survival expectancies ... smaller molars relative to their body size and ...
Cached Medicine News:Health News:Nurses Send Sutter a Clear Message 2Health News:Nurses Send Sutter a Clear Message 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2
... InterStim Therapy for Urinary Control offers ... retention and the symptoms of overactive ... significant symptoms of urgency-frequency alone or ... failed or could not tolerate more ...
... 4 Conti is a battery operated dual-channel therapy ... conditions described below. ELPHA 4 Conti also includes ... and faecal incontinence ELPHA 4 Conti provokes a ... user can feel which muscles need exercising. In ...
... Template Set is the HDR solution which ... technique. The template set consists of a ... sutured to the patient and is placed ... Grid Face Plates. The Stepper Holder is ...
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
Medicine Products: